Related Experiment Video
Updated: May 6, 2026

Use of a Rat Model to Study Ventral Abdominal Hernia Repair
Published on: October 2, 2017
Identifying potential drug targets for postoperative abdominal wall hernia using Mendelian randomization: a
Chensong Sun1,2, Ga Liu3, Taobin Liu4
1Center for Molecular Diagnosis and Precision Medicine, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, 1519 Dongyue Dadao, Nanchang, 330209, China.
Abstract:
This study aims to identify potential drug targets for postoperative abdominal wall hernia. Mendelian Randomization (MR) was applied to integrate data from druggable gene libraries, cis-pQTL data, and cis-eQTL data to analyze postoperative abdominal wall hernia in the FinnGen R11 population. Sensitivity and heterogeneity tests were conducted, along with reverse causality validation, to explore potential drug targets. A colocalization analysis was performed based on three cis-pQTL databases and cis-eQTL databases. Linkage disequilibrium was verified using Summary Data-Based Mendelian Randomization (SMR), and potential drug side effects were assessed using existing databases. Finally, drug target predictions and molecular docking studies were conducted. MR analysis revealed that, within the druggable target range, only one druggable gene, cathepsin S (CTSS) (FDR < 0.05; OR = 1.13, 95% CI = 1.06-1.20, P = 6.79 × 10e-5), was positively correlated with postoperative abdominal wall hernia. Colocalization analysis showed PPH4 > 0.7 in the cis-pQTL and cis-eQTL gene window of ± 50 kb. A key variant (rs41305070) was identified. Evaluation of drug side effects and molecular docking demonstrated that CTSS holds potential as a promising druggable target. Elevated levels of CTSS increase the risk of postoperative abdominal wall hernia, making CTSS a promising therapeutic target for this condition.
Related Concept Videos
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Pharmacogenomics: Identification of New Drug Targets

